Tumor vaccination strategies combined with autologous peripheral stem cell transplantation

Annals of Oncology

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Kwak, L W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Lymphoma; T cell immunity; Tumor vaccine

Indexed keywords

CANCER VACCINE;

CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELLULAR IMMUNITY; DRUG FORMULATION; HUMAN; LYMPHOMA; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0031920475     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_1.S41     Document Type: Review

References (36)

1. Stevenson GT, Stevenson FK. Antibody to molecularly-defined antigen confined to a tumor cell surface. Nature 1975; 254: 714-6.
2. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 1971; 68: 3130-5.
3. L domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol 1980; 11: 29-35.
4. Daley MJ, Gebel HM, Lynch RG. Idiotype-specific transplantation resistance to MOPC-315: Abrogation by post-immunization thymectomy. J Immunol 1978; 120: 1620-4.
5. Bridges SH. Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol 1978; 121: 479-83.
6. Freedman PM, Autry JR, Tokuda S et al. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst 1976; 56: 735-40.
7. Sugai S, Palmer DW, Talal N et al. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J Exp Med 1974; 140: 1547 58.
8. George AJT, Folkard SG, Hamblin TJ et al. Idiotypic vaccination as a treatment for a B-cell lymphoma. J Immunol 1988; 141: 2168-74.
9. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B-cell lymphoma: Combination of idiotype immunization and cyclophosphamide. J Immunol 1988; 141: 3227 33.
10. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209-15.
11. Kwak LW, Campbell MJ, Zelenetz AD et al. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: Active immunization with tumor-derived idiotypic immunoglobulin. Blood 1990; 76: 2411 7.
12. Skorski T, Kawalec M. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic 2F1 mice after lethal irradiation and reconstitution with bone marrow purged in leukemia with mafosfamide (ASTA Z 7654). Bone Marrow Transplant 1987; 2: 435.
13. Witherspoon RP, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time post-transplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58: 360.
14. Gorin NC, Muller JY, Solmon C et al. Immunocompetence following autologous bone marrow transplantation. Exp Hematol 1979; 7: 327.
15. Wimperis JZ, Prentice HG, Karayiannis P et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339.
16. Kwak LW. Vaccination strategies with tumor antigen in patients with lymphoma undergoing bone marrow transplantation. In Spitzer T. Mazumder A (eds): Immunotherapy and Bone Marrow Transplantation. Armonk, NY: Futura Publishing 1995; 137-51.
17. Kwak LW, Campbell MJ, Zelenetz AD et al. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy. Blood 1991; 78: 2768-72.
18. Stoner RD, Bond VP. Antibody formation by transplanted bone marrow, spleen, lymph nodes and thymus cells in irradiated recipients. J Immunol 1963; 91: 185.
19. Gengozian N, Makinodan T, Shekaraehi IC. Transplantation of antibody-forming cells in lethally irradiated mice. J Immunol 1961; 86: 13.
20. Garver RM, Santos GW, Cole LJ. Specific hemagglutinins in X-irradiated, bone marrow treated mice following differential immunization of host and donor. J Immunol 1959; 83: 57.
21. Gross-Wilde H, Krumbacher K, Schuning F et al. Immune transfer studies in canine allogeneic marrow graft donor-recipient pairs. Transplantation 1986; 42: 64.
22. Starling KA, Falletta JM, Fernbach DJ. Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. Exp Hematol 1975; 3: 244
23. Lum LG, Munn NA, Schanfield MS et al. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986; 67: 582.
24. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986; 6: 389.
25. Kato S, Yabe H, Yabe M et al. Studies on transfer of varicellazoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood 1990; 75: 806.
26. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995; 345: 1016.
27. Kwak LW, Sternas LA, Jagannath S et al. T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood 1997; 90 (Suppl 1): 579a.
28. Kwak LW, Young HA, Pennington RW, Weeks SW. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996; 93: 10972.
29. Sternas L, Janik JE, Duffey PL et al. Early results of a clinical trial of therapeutic vaccination with Ig idiotype antigen for de novo follicular lymphoma. Blood 1996; 88 (Suppl 1): 672a.
30. Bendandi M, Sternas L, Reynolds CW, Kwak LW. Induction of autologous lymphoma-specific CD8+ T cells by patient-specific vaccination against follicular lymphoma in first remission. Blood 1997; 90 (Suppl 1): 249a.
31. Tao M-H, Levy R. Idiotype granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755.
32. Hawkins RE, Winter G, Hamblin TJ et al. A genetic approach to idiotypic vaccination. J Immunother 1993; 14: 273.
33. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nature Med 1996; 2: 1038.
34. Flamand V et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605.
35. Levitsky HI, Montgomery J, Ahmadzadeh M et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858.
36. Schultze JL, Cardoso AA, Freeman GJ et al. Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200.